Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All consecutive statin-naive patients with non ST-elevation acute coronary syndrome admitted to our institution and scheduled for early invasive strategy are considered for enrollment~Exclusion Criteria:~* Current statin treatment~* High-risk features warranting emergency coronary angiography (within 2 hours)~* Acute renal failure or end-stage renal failure requiring dialysis or serum creatinine ≥ 3 mg/dl~* Severe comorbidities which precluded early invasive strategy~* Contraindications to statin treatment~* Contrast media administration within the last 10 days~* Pregnancy~* Refusal of consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance \< 30 ml/min)
- Atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)

Based on this trial design, predict the completion outcome and termination type (if applicable).